QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Julian who wrote (786)	12/24/1999 11:24:00 PM
From: Julian	of 1321

Dr Julia Levy of QLT Phototherapeutics discusses Photodynamic Therapy on Informed Investors Radio carried on WMET 1150AM in Washington D.C. Senior executive, Dr. Julia Levy from QLT Phototherapetics, appeared on the one-hour show to discuss the latest developments on the importance of Visudyne therapy in AMD. The radio hosts on WMET called QLT Phototherapeutics the "PREMIER COMPANY IN PDT". Dr. Levy informed the listening audience that Visudyne was discovered/developed internally within QLT Phototherapeutics for AMD [essentially a 'designer drug' designed to be safe, effective with a minimal side effect profile], unlike photofrin which was developed by Tom Dorherty of Roswell Hospital. The agreement on Visudyne with Ciba Vision was that Ciba paid for 60% of the development costs while QLT's share is 40%. Going forward Ciba Vision is responsible for global marketing and QLT is responsible for manufacturing. Profits are shared 50/50. A good deal for QLT Phototherapeutics. Visudyne approval is expected prior Feb.12'00. Revenues will be in the range of $US650 million going forward according to Levy. Levy reiterated what was already known, the safety profile for Visudyne is benign and the drug is cleared [rapid clearance] from the body within 24 hours [designed to have minimal side effects]. John Rende, biotech analyst with Weintraqub Capital in San Francisco gave a further perspective and additonal insight into QLT Phototherapeutics. He described that the differentiating factor in PDT is that the drug used in PDT is able to concentrate in abnormally dividing cells [non-invasive tissue sparing ability] sparing the normal cells. In discussing QLT he mentioned QLT Phototherapeutics's pipeline that includes products in the area of oncology. Rende stated that the growth rate of a PDT company such as QLT Phototherapeutics is three fold that of mature biotech companies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next